LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, June‐Yong Lee, Jessica Thomes Pepin, Michael J. Sundborg, Horacio Astudillo‐de la Vega, Shin Nishio, Kun Wang, Kevin McIntyre,

Annals of Oncology

MedicineCancer ManagementGynecologyRecurrent Endometrial CancerLba41 DurvalumabDurva ± OlaparibCancer TreatmentOncologyRadiation OncologyGynecology OncologyMolecular OncologyEndocrine-related Cancer